Tempest Therapeutics, Inc. develops clinical-stage cell therapy and small-molecule product candidates for cancer and related disease areas. News about TPST centers on its dual-targeting CAR-T platform, including TPST-2003, a CD19/BCMA CAR-T therapy under development for relapsed or refractory multiple myeloma, and clinical updates from programs such as REDEEM-1 and POEMS-1.
Company updates also cover CAR-T manufacturing and technology-transfer work, partner-supported development activities, business development and licensing priorities, and the amezalpat small-molecule program. Recurring corporate news includes financial results, pipeline portfolio changes following acquired CAR-T assets, leadership appointments, and governance or capital-structure matters tied to the company’s Nasdaq-listed common stock.
Tempest Therapeutics (TPST) has appointed John W. Frederick to its board of directors, adding an executive with financial and capital markets experience. Frederick has more than three decades of executive leadership experience across public and private companies, spanning corporate finance, operations and business transformation.
Most recently, he served as Chief Financial Officer of Skillsoft, overseeing financial reporting, investor relations, capital markets and liquidity strategy. His previous roles include Skillsoft's Chief Transformation Officer, leadership positions at its former subsidiary SumTotal Systems, and financial and operating roles at Indigo Ag and Snagajob. He currently serves on the boards of MutualOne Bank and SenSanna. Tempest said his experience would support its priorities of disciplined capital deployment and development milestones for its in vivo CAR-T programs, which are designed to modify immune cells within the body.
Tempest Therapeutics (TPST) appointed Nancy Freda-Smith to its board of directors, where she will also serve as Chair of the Audit Committee.
Tempest is a clinical-stage biotechnology company focused on developing in vivo CAR-T therapies for cancer and autoimmune disease. Freda-Smith is described as a seasoned public company board director and senior finance and audit executive, with more than 30 years of experience in corporate governance, financial reporting, enterprise risk management, and regulatory compliance for global organizations.
She most recently served as Chief Audit and Risk Officer at Ralph Lauren, overseeing internal audit, Sarbanes-Oxley compliance, enterprise risk management, asset protection, cybersecurity resilience, and global control transformation for operations in over 30 countries and more than $7 billion in revenue. Her prior roles include Independent Director and Audit Committee member at Chuy’s Holdings and Managing Director at Deloitte & Touche, advising Fortune 500 companies on SEC reporting and complex accounting. She is a CPA, Certified Fraud Examiner, and holds a B.S. in Accounting from Boston College.
Tempest Therapeutics (TPST) entered an exclusive option agreement with Hebei Senlang Biotechnology for a CD7-targeted lentiviral in vivo CAR-T platform and associated product candidates. The portfolio includes a BCMA/GPRC5D dual-targeting in vivo CAR-T program in Phase 1 dose escalation for relapsed/refractory multiple myeloma.
Early clinical observations at the current highest evaluable dose show successful in vivo CAR-T generation and expansion, with no Grade 3 or higher cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome observed as of August 25, 2026. The initial safety profile supports continued dose escalation, with enrollment and follow-up ongoing. Tempest expects the lentiviral platform, if the option is exercised, to complement its CD7-targeted lipid nanoparticle in vivo CAR-T platform, which is planned to enter the clinic later in 2026, expanding its immune reset portfolio in hematologic malignancies and autoimmune diseases.
Tempest Therapeutics (TPST) entered definitive agreements for a private placement of 3,105,591 shares of common stock (or pre-funded warrants) plus series C and series D warrants, at a combined purchase price of $0.805 per share and accompanying warrants.
The deal is expected to generate approximately $2.5 million in upfront gross proceeds at closing, anticipated on or about September 14, 2026, before fees and expenses. Series C and D warrants to purchase up to an additional 3,105,591 shares each have an exercise price of $0.805 per share and could provide about $5 million of additional gross proceeds if fully exercised in cash, although there is no assurance of exercise. The warrants become exercisable upon stockholder approval of the underlying shares and expire six years (series C) and three years (series D) from the later of that approval date and the effectiveness of a resale registration statement. Net proceeds are intended for working capital and general corporate purposes.
Tempest Therapeutics (TPST) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:30 p.m. ET.
The presentation by President and CEO Matt Angel, Ph.D., will be available via webcast on Tempest’s investor relations website and will remain archived for two weeks after the event.
Tempest Therapeutics (Nasdaq: TPST) reported second quarter 2026 results and a business update, highlighted by a development collaboration with Hebei Senlang Biotechnology to advance in vivo CAR-T candidates, including lead program TPST-4003, with first patient dosing in an investigator-initiated trial in China anticipated in the fourth quarter of 2026 and initial data expected in the first half of 2027.
The company reported positive interim data for TPST-2003, showing a 100% complete response rate in 15 efficacy-evaluable, CAR-T-naïve patients across REDEEM-1 and POEMS-1, and selected Cincinnati Children’s AGCTC as lead manufacturing partner in preparation for a potentially registrational rrMM study later in 2026. Tempest ended the quarter with $0.8 million in cash, a quarterly net loss of $5.2 million, and year-to-date net loss of $32.9 million, driven by a $22.1 million acquired in-process R&D expense related to a February 2026 asset acquisition.
Tempest Therapeutics (Nasdaq: TPST) announced a development collaboration with Hebei Senlang Biotechnology for TPST-4003, a next-generation in vivo CAR-T candidate that combines proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct for autoimmune and oncology applications.
According to Tempest, Senlang will run a first-in-human investigator-initiated trial in China in approximately 10 patients with myasthenia gravis or multiple sclerosis, with first dosing expected in Q4 2026. The study aims to generate initial safety, pharmacodynamic and cellular kinetics data, with early safety and PD readouts anticipated as soon as the first half of 2027. Senlang is responsible for trial coordination and execution in China and receives an exclusive option to negotiate a license for TPST-4003 in China.
Tempest Therapeutics (Nasdaq: TPST) detailed its next-generation in vivo CAR-T platform and plans to advance lead candidate TPST-4003 into a first investigator-initiated trial in nervous system autoimmune diseases, initially myasthenia gravis and multiple sclerosis. The study is expected to enroll about 10 patients, with first dosing anticipated in the fourth quarter of 2026 and initial safety and pharmacodynamic data in the first half of 2027.
TPST-4003 combines Tempest’s CD7-targeted mRNA lipid nanoparticle (CD7-tLNP) delivery system with the dual-targeting CD19/BCMA CAR architecture used in TPST-2003, which previously showed a 100% complete response rate in interim Phase 1/2a data. The trial will assess safety, cellular kinetics, B-cell depletion and reconstitution, and disease-specific clinical activity. Tempest also highlighted preclinical in vivo CAR-T programs TPST-001 for non-B-cell hematologic malignancies and TPST-002 for solid tumors, all built on the CD7-tLNP platform engineered for broader T-cell reach, optimized delivery, and scalable in vivo CAR-T treatment.
Tempest Therapeutics (Nasdaq: TPST) appointed two independent directors, Drake Richey and John Yee, MD, MPH, to its Board effective June 4, 2026. They add experience in corporate finance and therapeutic product development, supporting Tempest’s CAR-T cell therapy portfolio and focus on growth and disciplined capital allocation.
Tempest Therapeutics (Nasdaq: TPST) entered a definitive agreement for the immediate cash exercise of warrants for 1,172,414 common shares at a reduced exercise price of $1.73 per share. This is expected to generate about $2 million in gross proceeds, plus up to $4 million from new short-term warrants if fully exercised.
The company will issue new unregistered short-term warrants for up to 2,344,828 shares at $1.73, expiring two years after issuance, and plans to use net proceeds for working capital and general corporate purposes.